SoftOx Solutions AS - New Equity Research Report Published by Analyst Group
2026-10-28 09:37:09
SoftOx Solutions AS ("SoftOx") announces that Analyst Group has published an
updated equity research report covering the Company.
The report provides an independent assessment of SoftOx's clinical development
programmes, market opportunities, strategic alternatives, and valuation ahead of
the anticipated Phase 2a proof-of-concept readout in H1 2027.
The full report is available here:
https://analystgroup.se/bolag/softox-solutions/softox-solutions
The analysis has been prepared by Analyst Group. The assessments, assumptions,
and valuations expressed in the report are those of Analyst Group and do not
constitute guidance or forecasts issued by SoftOx Solutions AS.
For further information, please contact:
Ulrik Spork, COB, Soft Solutions AS, +45 31 38 83 87
Ingrid Juven, CFO, SoftOx Solutions AS, +47 918 76 165
Mail: ir@soft-ox.com
About SoftOx Solutions AS:
SoftOx Solutions AS (ticker: SOFTX) is a clinical-stage pharmaceutical company
developing SIS (SoftOx Inhalation Solution), a novel inhaled anti-infective
therapy for the treatment of respiratory infections in the airways and lungs.
The Company is listed on Euronext Growth Oslo.
ny is listed on Euronext Growth Oslo.\